Skip to main navigation Skip to search Skip to main content

Lipid nanoparticle-mediated CRISPR/Cas9 delivery enables efficient trabecular meshwork gene editing in mice

Research output: Journal Publications and ReviewsRGC 21 - Publication in refereed journalpeer-review

3 Downloads (CityUHK Scholars)

Abstract

Lipid nanoparticles (LNPs) enable efficient mRNA delivery, yet their potential for ocular gene editing remains largely unexplored. Here, we systematically evaluated three LNP formulations containing distinct ionizable lipids, DLin-MC3-DMA, ALC0315, and SM102, for gene delivery to ocular tissues. Among them, SM102-based LNP encapsulating GFP mRNA (SM102-GFP) exhibited the highest transfection efficiency across three cultured ocular cells in vitro. Following intravitreal injection in mice, SM102-GFP achieved selective and robust expression in the trabecular meshwork (TM) without detectable retinal transfection. GFP expression in TM peaked at one week post-injection, declined by three weeks, and could be effectively re-induced by a second dosing of the same vector. Compared with adeno-associated viral (AAV) and adenoviral (Ad) vectors, SM102-GFP showed superior TM specificity and reduced retinal inflammation. Co-delivery of SpCas9 mRNA and sgRNA via SM102-based LNPs enabled efficient CRISPR-mediated knockout of Matrix Gla Protein (Mgp), a key inhibitor of TM calcification. Mgp knockout induced sustained intraocular pressure elevation and anterior chamber deepening with open angles, recapitulating features of primary open-angle glaucoma. Chronic ocular hypertension further led to Müller gliosis and ganglion cell complex thinning, indicative of progressive retinal stress. These findings establish SM102-based LNPs as a safe and efficient platform for TM-targeted gene editing and glaucoma modeling.

© 2025 The Authors.
Original languageEnglish
Article number114499
Number of pages13
JournalJournal of Controlled Release
Volume389
Online published2 Dec 2025
DOIs
Publication statusPublished - 10 Jan 2026

Funding

We thank Prof. Constance Cepko (Harvard Medical School), Prof. Shusheng Wang (Tulane University), Prof. Muayyad Al-Ubaedi (University of Oklahoma Health Sciences Center), Prof. Chi-Wai Do (The Hong Kong Polytechnic University) and Prof. Kingston Mak (City University of Hong Kong) for generously providing reagents and technical support. This research was funded by the Innovation and Technology Fund (GHP/223/21SZ) from the Hong Kong Innovation and Technology Commission; the Shenzhen Science and Technology Program, Shenzhen, China (No. SGDX20211123120001001); the General Research Funds (11103819, 11102922, and 11100723) from the Hong Kong Research Grants Council; the Hong Kong Health and Medical Research Fund (05160276 and 06172466) from the Hong Kong Food and Health Bureau; and the TUNG Biomedical Sciences Foundation.

Research Keywords

  • Gene editing
  • glaucoma
  • Intravitreal injection
  • Lipid nanoparticle (LNP)
  • mRNA
  • Trabecular meshwork

Publisher's Copyright Statement

  • This full text is made available under CC-BY 4.0. https://creativecommons.org/licenses/by/4.0/

RGC Funding Information

  • RGC-funded

Fingerprint

Dive into the research topics of 'Lipid nanoparticle-mediated CRISPR/Cas9 delivery enables efficient trabecular meshwork gene editing in mice'. Together they form a unique fingerprint.

Cite this